WuXi Biologics ISIN: KYG970081173 Forum: Aktien User: Summer.76

Ein sehr ausführlicher Artikel zur WuXi Bio und lässt sich auch ohne die App öffnen: China Securities: Maintain WuXi Biologics (02269) "overweight" rating target price of 163.48 Hong Kong dollars https://wap.eastmoney.com/a/202107162000870883.html

Etwas umfangreicher und für den Übersetzer: https://hk.on.cc/hk/bkn/cnt/finance/20210714/mobile/bkn-20210714073141592-0714_00842_001.html

WUXI BIO Projects 1H NP to Surge by Over 1.35x YoY http://www.aastocks.com/en/stocks/news/aafn-con/NOW.1112315/recommend-news WUXI BIO issued a positive profit alert. It is expected that the net profit for the six months ended June 30, 2021 will increase more than 135% compared with that for the corresponding period of last year. Such increase was primarily attributable to: the Group’s acceleration to undertake, promptly execute and generate revenue from existing and new COVID-19 projects to support and enable the Group’s global clients in the first half of 2021 in combatting against COVID-19; leading technology platform, best-in-industry timeline and excellent execution track record contributing to significantly higher revenue and market share of new integrated projects; and so on.

https://hk.investing.com/news/stock-market-news/article-176503 ... WuXi Biologics (2269.HK): Accelerate upward, target 175 Hong Kong dollars Source: GAIN Capital, TradingView WuXi Biologics (2269.HK), a Chinese biopharmaceutical service provider, has risen more than 15% so far in June and hit a record high. The investment bank Macquarie has given the company an "Outperform" rating, and expects that future growth will continue to be strong due to the support of the new coronavirus vaccine and antibody-drug complex project. Morgan Stanley also expects the global biological product outsourcing services to develop prosperously, and it is expected that WuXi Biologics will maintain its leading position in the Chinese market and give it an "overweight" rating. From a technical point of view, as shown on the daily chart, WuXi Biologics stock price has accelerated recently, breaking the rising channel pulled from March, and the technical landscape is extremely bullish. Currently, it is trading above the 20- and 50-day moving averages, and the relative strength indicator has not shown a clear bearish divergence. The stock price has not seen fatigue and should rise to the upside target of HK$160.00 and HK$175.00. The main support (stop loss) for the bullish trend has been raised to HK$118.00.

Enthält auch einen längeren Part in Bezug auf die WuXi: Hong Kong stocks have lost the 250-day bull-bear boundary and regained a category that should not be touched. https://www.businesstimes.com.hk/articles/134057/%E6%B8%AF%E8%82%A1%E5%88%86%E6%9E%902021-250%E5%A4%A9%E7%B7%9A-%E7%89%9B%E7%86%8A%E5%88%86%E7%95%8C%E7%B7%9A-%E6%B8%AF%E4%BA%A4%E6%89%80-%E5%82%B5%E5%88%B8%E9%80%9A-%E8%B7%A8%E5%A2%83%E7%90%86%E8%B2%A1%E9%80%9A-%E5%85%A7%E5%9C%B0%E7%B6%B2%E7%B4%84%E8%BB%8A%E5%B7%A8%E9%A0%AD%E6%BB%B4%E6%BB%B4%E5%87%BA%E8%A1%8C

Hong Kong stocks move | WuXi Biologics (2269 HK) rose more than 4%, optimistic about many institutions https://m.jrj.com.cn/madapter/hk/2021/07/07135433057952.shtml

Der englische Artikel lässt sich vorteilhafter lesen als der chinesische: Macquarie Sees Limited New Regulation Impact on WUXI BIO's Profit, with Buying Chance  http://www.aastocks.com/en/stocks/news/aafn-con/NOW.1110680/recommend-news

"Big Bank Report" Macquarie Material WuXi Biologics (02269 HK) Profits Affected by New Regulatory Requirements Limited Means Usher in Buying Opportunities http://www.aastocks.com/tc/stocks/news/aafn-news/NOW.1110680/1

Alles entspannt…😴 heute wieder mit einer Gegenbewegung…

Ups... bin gespannt wie sich weiter entwickelt. Sie lief bis vor kurzem ja top

Oh man oh man 🤦‍♂️ Aber 8% sind schon ein echt heftiger Abschlag für so eine Nachricht 🤔

Etwas ausführlicher begründet und ein Fall für den Übersetzer: CRO stocks plummeted and worries that the new policy reduces the number of orders https://m.hkej.com/landing/mobarticle2/id/2845856/%E3%80%90%E7%95%B0%E5%8B%95%E6%9D%BF%E5%A1%8A%E3%80%91CRO%E8%82%A1%E6%80%A5%E6%8C%AB+%E6%86%82%E6%96%B0%E6%94%BF%E4%BB%A4%E8%A8%82%E5%96%AE%E6%95%B8%E9%87%8F%E9%99%8D

Und der Kurs steht aktuell noch deutlich tiefer 📉: Hong Kong stocks move | WuXi Biologics (02269) fell over 5% and led the decline in CRO concept stock CDE publicly solicits opinions on guiding principles for the development of innovative anti-tumor drugs https://finance.sina.cn/hkstock/ggyw/2021-07-06/detail-ikqcfnca5193370.d.html?from=wap Pharmaceutical outsourcing stocks fell across the board, as of this writing, medicine WuXi biologics (02269) fell 6.38 percent to HK $ 129.2; Tiger medicine (03347) fell 4.12 percent to HK $ 170; into Hong Long (03759) fell 2.75%, report 187.6 Hong Kong dollars; WuXi AppTec (02359) fell 2.4% to 170.8 Hong Kong dollars. On the news, on July 2, the Center for Drug Evaluation (CDE) of the National Medical Products Administration issued the "Notice on the Public Solicitation of Opinions on the Guiding Principles for Clinical Research and Development of Anti-tumor Drugs Oriented by Clinical Value". The market tends to believe that the changes in the BSC selected for clinical controlled trials in the draft opinion will affect the prosperity of CXO in the future. Because this change will directly reduce the possibility of drugs developed using the me-too method on the market in the future, which will affect the number of new drug companies' products and reduce the number of orders that CXO companies can obtain.

Donnerstag ist Feiertag in HK

WuXi Biologics (02269 HK) was reduced by executive director Chen Zhisheng's holdings of 2,204,400 shares https://m.jrj.com.cn/madapter/hk/2021/06/29083833013998.shtml Gelonghui APP was informed that according to the latest equity disclosure information of the Stock Exchange, on June 24, 2021, WuXi Biologics (02269.HK) was reduced by Executive Director Chen Zhisheng on the floor at an average price of HK$136.3166 per share to 2.204 million shares. The investment is about 300.5 million Hong Kong dollars. After the reduction, Chen Zhisheng's latest shareholding number was 118,254,584 shares, and the shareholding ratio fell from 2.84% to 2.79%.

Tolle Aktie mit sehr schönem Chartbild....bin durch Beate Sanders darauf gestoßen und bei €6 eingestiegen....von mir aus könnten Sie bei €20 den nächsten Split durchführen...☺☺☺